GLP 1 kidney benefits outrun weight loss in a Kidney Week evidence review

The GLP 1 kidney benefits seen in large outcome trials do not simply follow the scale, nephrologists argued at ASN Kidney Week 2026. A session on obesity and chronic kidney disease set the FLOW trial, a tirzepatide kidney analysis and a large dialysis cohort side by side, then asked what the drugs cannot do alone. No molecule moves on our board. The value of the review is in how it grades the evidence: where it is firm, where it is exploratory, and which patients it does not yet cover.

Why kidney protection does not track the scale

Talat Alp Ikizler of Vanderbilt University Medical Center opened with the study that anchors the field. FLOW, a phase 3 semaglutide chronic kidney disease trial sponsored by Novo Nordisk, randomised 3,533 adults with type 2 diabetes and kidney disease to weekly semaglutide or placebo. Over a median of 3.4 years, the drug lowered the risk of the main kidney composite by 24 percent, a hazard ratio of 0.76. Weight loss in the same study was modest, 6.2 percent on semaglutide against 1.6 percent on placebo. Ikizler used that contrast to make his central point. If a drug that removes only a few percent of body weight still protects the kidney, the benefit must also run through other routes, since GLP 1 receptors sit in many organs.

He also drew limits. Ikizler warned that the weight lost on these drugs includes lean tissue as well as fat, which matters in a population already prone to muscle loss. He said FLOW results should not be stretched to people on dialysis or living with a kidney transplant, because the trial did not study them. He described obesity as a chronic, relapsing disease in which the body answers weight loss with more hunger and lower energy use, so regain is common when treatment stops. For readers who follow the pipeline, the lesson is that GLP 1 kidney benefits rest on outcome trials in defined groups. Each new group, from dialysis to transplant, needs its own evidence before the claim can be extended to it.

Tirzepatide kidney data from SURPASS CVOT

The second data point came from Eli Lilly. SURPASS-CVOT was a heart outcome trial that compared tirzepatide, a GIP and GLP 1 dual agonist, with dulaglutide, an older GLP 1 drug, in people with type 2 diabetes and established atherosclerotic disease. A prespecified exploratory kidney analysis, published this year in The Lancet Diabetes and Endocrinology, followed 6,586 people on tirzepatide and 6,579 on dulaglutide for a median of four years. Major kidney events occurred in 6.0 percent of the tirzepatide group and 7.6 percent of the dulaglutide group, a hazard ratio of 0.77. That is a 23 percent lower risk against an active drug that itself acts on the GLP 1 receptor, not against placebo.

That is a 23 percent lower risk against an active drug that itself acts on the GLP 1 receptor, not against placebo.

The kidney composite combined new persistent macroalbuminuria, a sustained fall in eGFR of at least half, kidney failure and death from kidney disease. The authors report that the overall gain came mostly from fewer new cases of macroalbuminuria in people at low to moderate kidney risk, and from slower eGFR decline in people at high risk. Nausea, vomiting and diarrhoea were more common on tirzepatide, and Lilly funded the work. Because the analysis was exploratory and the trial was built around heart outcomes, it supports a hypothesis rather than a kidney label. The SURPASS-CVOT registry record lists the trial as completed, with 13,299 people enrolled; the paper set aside 134 who were randomised in error.

What the dialysis evidence can and cannot show

Ikizler then turned to people already on dialysis, the group that FLOW left out. He cited a national US cohort from researchers at New York University, published in 2025 in the Clinical Journal of the American Society of Nephrology. Among 151,649 adults with type 2 diabetes who started dialysis between 2013 and 2021, use of a GLP 1 drug was linked to a 23 percent lower risk of death and a 66 percent higher chance of being placed on a kidney transplant waitlist. Ikizler argued that weight loss on these drugs may help some patients meet listing criteria they could not reach before. That route is plausible, and for patients waiting on dialysis it would matter a great deal.

The design limits what those numbers mean. This was an observational study, so the authors balanced the groups with statistical weights but could not randomise them, and people who were prescribed a GLP 1 drug may differ from those who were not in ways the records do not show. The same paper found a 32 percent higher risk of diabetic retinopathy with GLP 1 use, while acute pancreatitis, gallbladder problems and medullary thyroid cancer showed no rise. Those findings belong next to the survival signal, not beneath it. The table gathers the main figures from the session and the papers behind them, with the type of evidence for each, because the weight a reader gives a number should depend on how it was produced.

Where GLP 1 kidney benefits meet their limits

Other speakers widened the frame. Amy Mottl of the University of North Carolina called the drugs "probably the greatest medication for CKD that's come along in 100 years," but added that "they alone will not be sufficient for patients." She urged routine conversations about diet and movement, and stressed resistance exercise, because sarcopenic obesity affects up to a quarter of people with chronic kidney disease and can worsen with weight loss. Ifeoma Ulasi of the University of Nigeria pointed to a different ceiling. In a meta-analysis of 27 GLP 1 obesity trials that she cited, 84.2 percent of 1,859 trial sites were in high income countries, so the populations with the heaviest disease burden are the least studied.

Ulasi also cited a cost study in which the cheapest GLP 1 drug took 1.6 percent of a monthly minimum wage in France but 110.4 percent in Sri Lanka. Her point was that the open question is whether health systems can find, fund and deliver treatment, not whether the drugs work. For our board, the retatrutide kidney trial shows how a newer molecule is now testing kidney endpoints directly. The incretins class page lists every GLP 1 based molecule we track. Each will face the questions this session raised on lean mass, dialysis and access, and the full session report sets out every speaker's case.

Conclusion

The GLP 1 kidney benefits discussed at Kidney Week rest on one randomised kidney trial, one exploratory analysis against an active comparator and one observational dialysis cohort. Together they point to protection that does not depend on weight loss alone, but they give no trial grade evidence for people on dialysis or with a transplant. The next checkpoint is dedicated kidney outcome trials for newer molecules such as retatrutide, and any trial that enrols people on dialysis. This story is research news, not medical advice.